Fresh analysis suggests that people who stop using blockbuster GLP-1 drugs like semaglutide or tirzepatide tend to recover reduced body mass at a significantly accelerated pace than those who end conventional lifestyle regimens.
Research printed in a leading medical journal points out that while obese people frequently drop a large proportion of their total mass while undergoing treatment, the mass returns at an estimated rate of 0.8 kg per month once they quit.
"People purchasing such drugs need to be aware of the potential of quick rebound weight gain when the medication ends," stated researcher Dr. Susan Jebb.
This pace of recovery means a return to pre-treatment weight in about one and a half years.
Analyzing Therapies
The analysis, which examined 37 of trials involving thousands of patients, contrasted the outcomes of the injectable medications with other pills.
The team point out that individuals who shed pounds through diet and exercise generally see a less rapid weight regain—approximately 0.1 kg a month—after stopping.
Understanding the Fast Regain
Doctors believe the way of the drugs accounts for the accelerated rebound.
These medications imitate a natural hormone called glucagon-like peptide-1, which moderates appetite.
"Artificially providing GLP-1 levels several times higher than normal may cause the body to produce less of its endogenous GLP-1, and may also diminish sensitivity to its effects," said Dr. Adam Collins, a nutrition researcher.
"Discontinuation of this medication means appetite is unsuppressed, making excessive eating much more probable."
A Lifelong Issue?
The NHS recommend the jabs for individuals with weight-linked medical conditions, accompanied by prescribed lifestyle changes.
Professionals argue that, due to the significant potential of weight regain, the therapy might need to be ongoing.
This view is echoed by pharmaceutical companies, who say that the results "underscore the chronic character of excess weight," comparing it to managing conditions like high blood pressure.
Patient Testimonies
Individuals who have discontinued the jabs explain a powerful return of hunger.
"It was like something that goes on and you become extremely hungry," said one woman.
The struggle is compounded if patients have not established lasting lifestyle or habit modifications during treatment.
Widespread Adoption
Survey data suggest that millions of people in the UK have tried weight-loss jabs in the last 12 months, with demand being substantial.
- Adoption is greater among women than men.
- The 40s and 50s demographic shows the highest usage rates.
- A large proportion obtain the medications through private prescriptions rather than the NHS.
Ultimately, experts emphasize that while these medications are effective agents for weight loss, they are not a permanent solution and maintained weight loss hinges on integrated behavioural changes.
